Latest News Archive

Please select Category, Year, and then Month to display items

National Lotteries Commission funded projects, the pride of UFS

17 April 2019 | Story Mamosa Makaya

The University of the Free State (UFS) has over many years embarked on developmental projects to improve and upgrade its sports facilities, sports research, medical research, arts and cultural programmes and community focused programmes. These projects were made possible with the financial support of the National Lotteries Commission (NLC) which has provided funding through grants to the UFS since 2006. The UFS office of Institutional Advancement (IA) hosted the NLC on the Bloemfontein Campus on 5 April 2019, where a presentation on the success of projects was made. The role of the IA office is to ensure that the university complies with reporting requirements set out in the grant agreements and that the university maintains good relations with the NLC over the long term.

Funding fortifies UFS projects
Feedback on the success and impact of various projects was presented, such as the visual arts project. This includes the public sculpture project funded with over R3 million in 2009, which brought about the creation of outdoor sculptures that can be seen on the university grounds produced by local and regional sculptors. Feedback was provided by Ms Angela de Jesus, Curator, UFS Arts Collection and Assistant Director: Johannes Stegmann Gallery.

In 2010 the NLC funded the upgrading of the UFS swimming pool for more than R2 million. The pool was rebuilt to bring it up to Olympic standards, allowing UFS students to have a facility at which to train for international swimming competitions. Feedback on the project was provided by Mr Frans van der Wat, Deputy Director: KovsieSport. Other funded projects are the Khoisan early learning centre, which teaches young learners on the history and culture of the “first people” of South Africa, and the Arts in Schools Project, which were both funded in 2009 for more than R6 million combined. More funded projects include the upgrading of the Johannes Stegmann Gallery in 2017, research into swimming in the Free State, and equipment for the South African Doping Control Laboratory (SADOCol), which is the only laboratory of its kind in Africa, which were funded between 2010 and 2012, totalling R4.8million.

Community development and engaged scholarship
After the change in the mandate of the Provincial Arts Council of the Free State (PACOFS) after 1996, many local dramatic arts professionals in the province were faced with dwindling work opportunities. The UFS, through the Department of Drama and Theatre Arts, stepped in to create arts programmes that would help develop and retain the skills of local performers and playwrights and an opportunity for them to be trained and directed by UFS and industry-based professional directors.

Prof Nico Luwes, from the UFS Department of Drama and Theatre Arts, said: “I initiated the formation of the Free State Theatre Acts (FACTS) as a section 21 Company with committee members from UFS staff and local actors, with the aim of creating work for professional actors in the greater Bloemfontein area.” A combination of grants from the NLC and the UFS Department of Drama, between 2006 and 2010 resulted in 19 professional plays and four professional musicals, performed by Free State professional artists including community players from Heidedal, Botshabelo and drama students, using English, Afrikaans and Sesotho. These initiatives brought together students and artists from different linguistic and cultural backgrounds, who worked together to perform at local and national arts festivals. Although the NLC will not be funding arts and culture projects at universities in the 2019-2020 financial year, the university is hopeful to be considered in the future.

The UFS and NLC have had a successful working relationship and the feedback session aimed to strengthen the ties between them. Members of the board of the NLC expressed pride at how the UFS has developed not only its own projects, but the Free State community as well. The team was treated to an art exhibition of the work of Cape Town-based artist Ieshaan Adams at the Johannes Stegmann gallery.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept